P001 Advances in Clinical Research: Highlights from the Innovation Academy’s Scientific Abstracts
DESCRIPTION
This session will highlight the most impactful and clinically relevant scientific abstracts submitted to the 2026 Innovation Academy.
LEARNING OBJECTIVES
Present selected innovative or impactful scientific abstracts at the 2026 Innovation Academy
Discuss implications of the research findings to clinical practice
SCHEDULE
10:00 AM
Diagnostic Accuracy and Equity of Four Consumer AI Chatbots on Smartphone Dermatological Images: A Comparative Study Using the SCIN Dataset
Kevin Tabatabaei
10:10 AM
Subgroup Analysis of the Efficacy and Safety of VDPHL01, a Novel Investigational Extended-Release (ER) Oral Minoxidil Tablet, in Male Patients with Pattern Hair Loss (PHL) by Age
Maria K. Hordinsky, MD, FAAD
10:20 AM
Once-daily oral zasocitinib demonstrates robust and consistent efficacy across subgroups of adults with moderate-to-severe plaque psoriasis, including difficult-to-treat populations: an integrated analysis of two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002)
Mark Lebwohl, MD, FAAD
10:30 AM
The Specialization Paradox: When Medical AI Advancement Deepens Diagnostic Inequality Across Skin Tones
Victoria Koziarz
10:40 AM
Characterizing Factors Associated with Mohs Micrographic Surgery Surgical Site Infections in Immunosuppressed Myelodysplastic Syndrome Patients: A Retrospective Study
Anvita Anumolu
10:50 AM
Tumor Mutations Predict Immunotherapy Response in Cutaneous Squamous Cell Carcinoma
Haley Neff
11:00 AM
Evaluating the Impact of Comorbidities on Mortality in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review and Meta-Analysis
Emily Sheetz, MS
11:10 AM
Prevalence of mixed nutritional deficiency in patients with refractory skin toxicity during amivantamab therapy
Jason Kao, PA-C
11:20 AM
Clascoterone Cream 1% is Safe and Effective for Papulopustular Rosacea: A Phase 2 Clinical Trial
Lucie Joerg
11:30 AM
Zasocitinib, a once-daily oral TYK2 inhibitor, demonstrates efficacy at high impact sites in adults with moderate-to-severe plaque psoriasis: results from two randomized phase 3 trials (LATITUDE-PsO-3001 and 3002)
Leon H. Kircik, MD, FAAD
11:40 AM
Granuloma Annulare and GLP-1 Receptor Agonist Exposure: Temporal Analysis Across 267 Patients
Ryan Hirsh
11:50 AM
A Multi-center, Phase 2 Study of Hemoporfin for the Treatment of Port-Wine Birthmark
Jeanette Black, MD, FAAD
DIRECTOR
Amit Garg, MD, FAAD
Northwell Health
CO-DIRECTOR
Sheila Shaigany, MD, FAAD
Northwell
SPEAKERS
Anvita Anumolu
Jeanette Black, MD, FAAD
UnionDerm
Ryan Hirsh
University of Kansas School of Medicine
Maria K. Hordinsky, MD, FAAD
University of Minnesota
Lucie Joerg
Albany Medical College
Jason Kao, PA-C
Stanford University
Leon H. Kircik, MD, FAAD
Mount Sinai Medical Center, New York, NY
Victoria Koziarz
University of Limerick
Mark Lebwohl, MD, FAAD
Icahn School of Medicine at Mount Sinai
Haley Neff
UMass Medical School / Brigham and Women’s
Emily Sheetz, MS
Eastern Virginia Medical School at Old Dominion University
Kevin Tabatabaei
Mayo Clinic
HANDOUTS
DISCLOSURES
Anvita Anumolu
No financial relationships exist with ineligible companies.
Jeanette Black, MD, FAAD
AbbVie – Speaker/Faculty Education(Honoraria); Allergan, Inc. – Advisory Board(Honoraria), Investigator(Fees); Calissa Therapeutics – Consultant (1099 relationship)(Honoraria); Evolus, Inc. – Speaker(Honoraria); Galderma USA – Advisory Board(Honoraria), Independent Contractor(Honoraria), Investigator(Fees), Speaker(Honoraria); Merz Pharmaceuticals, LLC – Advisory Board(Honoraria), Investigator(Fees), Investigator(Grants/Research Funding), Speaker(Honoraria); Revance Therapeutics, Inc. – Advisory Board(Honoraria), Investigator(Fees);
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Almirall – Consultant (1099 relationship)(Fees); Bluefin Biomedicine – Consultant (1099 relationship)(Fees); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Leo Pharma – Advisory Board(Honoraria); Navigator Medicines – Consultant (1099 relationship)(Fees); Novartis – Consultant(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Fees); Otsuka Pharmaceutical Co., Ltd. – Consultant (1099 relationship)(Fees); Priovant Therapeutics – Consultant (1099 relationship)(Fees); Sanofi/Regeneron – Advisory Board(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Fees); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Fees); UCB – Consultant(Honoraria); Zura Bio – Consultant (1099 relationship)(Fees);
Ryan Hirsh
No financial relationships exist with ineligible companies.
Maria K. Hordinsky, MD, FAAD
AbbVie – Investigator(Grants/Research Funding); Cassiopea – Investigator(Grants/Research Funding); Eli Lilly and Company – Investigator(Grants/Research Funding); McGraw-Hill Companies – Other(Fees); National Alopecia Areata Foundation – Investigator(Grants/Research Funding); Pfizer Inc. – Investigator(Grants/Research Funding); Sun Pharmaceuticals – Investigator(Grants/Research Funding); UpToDate, Inc – Other(Fees); VeraDermics Inc. – Investigator(Grants/Research Funding);
Lucie Joerg
No financial relationships exist with ineligible companies.
Jason Kao, PA-C
No financial relationships exist with ineligible companies.
Leon H. Kircik, MD, FAAD
3M Pharmaceuticals – Investigator(Grants/Research Funding), Speaker(Honoraria); Abbott Laboratories – Speaker(Honoraria); Ablynx – Investigator(Grants/Research Funding); Acambis – Investigator(Grants/Research Funding); Allergan, Inc – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Honoraria), Speaker(Honoraria); Almirall – Consultant(Honoraria); Alumis – Advisory Board(Honoraria); Amgen – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); AnaptysBio – Investigator(Grants/Research Funding); Apogee Therapeutics – Consultant (1099 relationship)(Honoraria); Apollo Therapeutics Ltd – Investigator(Grants/Research Funding); Aqua – Advisory Board(Honoraria); Arcutis, Inc. – Investigator(Grants/Research Funding); Astellas Pharma US, Inc – Investigator(Grants/Research Funding), Speaker(Honoraria); Asubio Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Bayer Consumer Healthcare Pharmaceuticals – Investigator(Grants/Research Funding); Beiersdorf, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Biofrontera – Consultant (1099 relationship)(Honoraria); Biogen – Advisory Board(Honoraria); Biolife – Investigator(Grants/Research Funding); Biopelle, Inc. – Investigator(Grants/Research Funding); Boehringer Ingelheim – Investigator(Grants/Research Funding); Botanix Pharmaceuticals – Consultant(Honoraria); Breckinridge Pharma – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Cassiopea SpA – Consultant(Honoraria); Celgene – Consultant(Honoraria), Investigator(Grants/Research Funding); Cellceutix – Investigator(Grants/Research Funding); Centocor Ortho Biotech Inc. – Investigator(Grants/Research Funding); ChemoCentryx – Investigator(Grants/Research Funding); ColBar LifeScience Ltd. – Advisory Board(Honoraria), Consultant(Honoraria); CollaGenex Pharmaceuticals, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Connetics Corporation – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding); Coria Laboratories – Investigator(Grants/Research Funding); Dermata Therapeutics – Investigator(Grants/Research Funding); Dermavant Sciences, Inc. – Investigator(Grants/Research Funding); Dermik Laboratories, a business of sanofi-aventis U.S. LLC – Speaker(Honoraria); Dow Pharmaceutical Sciences, Inc. – Investigator(Grants/Research Funding); DUSA Pharmaceuticals, Inc. – Investigator(Grants/Research Funding); Eli Lilly – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Embil Pharmaceuticals, Co., Ltd – Speaker(Honoraria); Enveda Biosciences – Investigator(Grants/Research Funding); EOS – Advisory Board(Honoraria); Feldan Therapeutics – Consultant (1099 relationship)(Honoraria); Ferndale Laboratories, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Galderma Laboratories, L.P. – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Genentech, Inc. – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); GlaxoSmithKline – Investigator(Grants/Research Funding); Healthpoint – Investigator(Grants/Research Funding); Incyte Corporation – Investigator(Grants/Research Funding); Intendis, Inc. – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding); Isdin – Advisory Board(Honoraria); Johnson & Johnson Consumer Products Company – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria), Stockholder(Stock); Kymera Therapeutics – Advisory Board(Honoraria); L'Oreal – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Laboratory Skin Care, Inc. – Consultant(Honoraria); Leo Pharma Inc – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); MC2 Therapeutics – Consultant(Honoraria); Medical International Technologies – Consultant(Honoraria); Medicis Pharmaceutical Corporation – Investigator(Grants/Research Funding); Merck – Investigator(Grants/Research Funding); Merck & Co., Inc – Consultant(Honoraria); Merck Serono – Speaker(Honoraria); Merz Pharmaceuticals, LLC – Consultant(Honoraria); NanoBio Corporation – Advisory Board(Honoraria), Investigator(Grants/Research Funding); Nektar Therapeutics – Consultant (1099 relationship)(Honoraria); Novartis Pharmaceuticals Corp. – Consultant(Honoraria), Investigator(Grants/Research Funding); Nucryst – Investigator(Grants/Research Funding); Obagi Medical Products – Investigator(Grants/Research Funding); Onset Dermatologics – Investigator(Grants/Research Funding), Speaker(Honoraria); Organon Biosciences SRL – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Ortho Dermatologics – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Oruka Therapeutics – Advisory Board(Honoraria); Pfizer Inc. – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Pharmaderm – Investigator(Grants/Research Funding), Speaker(Honoraria); Promius Pharma, LLC – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding); PuraCap Pharmaceutical – Consultant(Honoraria); QLT Inc. – Investigator(Honoraria); Regeneron Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Sagimet Biosciences – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria); Sandoz, a Novartis company – Investigator(Grants/Research Funding); Sanofi – Advisory Board(Honoraria), Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); SkinMedica, Inc. – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Stiefel a GSK company – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Taro Pharm – Consultant(Honoraria), Investigator(Grants/Research Funding); TolerRx – Investigator(Grants/Research Funding); Triax Pharmaceuticals, LLC – Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); UCB Pharma – Consultant (1099 relationship)(Honoraria), Speaker(Honoraria); Valeant Pharmaceuticals International – Advisory Board(Honoraria), Consultant(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Vellera – Stockholder Private Company(No Compensation Received); Warner Chilcott – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Xenoport, Inc. – Investigator(Grants/Research Funding); Zalicus – Investigator(Grants/Research Funding);
Victoria Koziarz
No financial relationships exist with ineligible companies.
Mark Lebwohl, MD, FAAD
AbbVie – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Added Health – Consultant (1099 relationship)(Honoraria); Aikium – Consultant (1099 relationship)(Honoraria); Almirall – Consultant(Honoraria); AltruBio Inc. – Consultant(Honoraria); Alumis – Consultant (1099 relationship)(Honoraria); Amgen – Consultant (1099 relationship)(Honoraria); Apogee Therapeutics – Consultant(Honoraria); Arcutis, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); AstraZeneca – Consultant (1099 relationship)(Honoraria); Atomwise – Consultant(Honoraria); Avotres, Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Bausch Health – Consultant (1099 relationship)(Honoraria); Boehringer Ingelheim – Consultant(Honoraria), Investigator(Grants/Research Funding); Bristol Myers Squibb – Investigator(Grants/Research Funding); Bristol-Myers Squibb – Consultant(Honoraria); Cara Therapeutics – Investigator(Grants/Research Funding); Castle Biosciences, Inc – Consultant(Honoraria); Celltrion – Consultant(Honoraria); Clexio Biosciences, Ltd – Investigator(Grants/Research Funding); CoreEvitas, LLC – Consultant(Honoraria); Dermavant Sciences – Consultant(Honoraria), Investigator(Grants/Research Funding); Dermsquared – Consultant (1099 relationship)(Honoraria); Edesa Biotech – Consultant (1099 relationship)(Honoraria); Eli Lilly – Consultant (1099 relationship)(Honoraria); Eli Lilly and Company – Investigator(Grants/Research Funding); Evommune, Inc. – Consultant(Honoraria); Facilitation of International Dermatology Education – Consultant(Honoraria); Forte Biosciences – Consultant(Honoraria); Galderma – Consultant(Honoraria); Genentech, Inc. – Consultant(Honoraria); Incyte Corporation – Consultant(Honoraria), Investigator(Grants/Research Funding); Inozyme Pharma – Investigator(Grants/Research Funding); J&J Innovative Medicine – Consultant (1099 relationship)(Honoraria); Janssen Research & Development, LLC – Investigator(Grants/Research Funding); Leo Pharma A/S – Consultant(Honoraria); Mayne Pharma Group – Consultant (1099 relationship)(Honoraria); Meiji Seika Pharma Co., Ltd – Consultant(Honoraria); Mindera – Consultant(Honoraria); Mirum Pharmaceuticals, Inc. – Consultant (1099 relationship)(Honoraria); MoonLake Immunotherapeutics – Consultant (1099 relationship)(Honoraria); New York College of Podiatric Medicine – Speaker/Faculty Education(Honoraria); Oruka Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Pfizer Inc. – Consultant(Honoraria), Investigator(Grants/Research Funding); Revolo Therapeutics – Consultant (1099 relationship)(Honoraria); Sanofi/Regeneron – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Seanergy Maritime Holdings Corp. – Consultant(Honoraria); Strata Skin Sciences – Consultant(Honoraria); Sun Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Takeda Pharmaceuticals USA Inc – Consultant (1099 relationship)(Honoraria); Teva Pharmaceutical Industries Ltd. – Consultant (1099 relationship)(Honoraria); Trevi Therapeutics – Consultant(Honoraria); UCB – Investigator(Grants/Research Funding); Verrica Pharmaceuticals Inc – Consultant(Honoraria);
Haley Neff
No financial relationships exist with ineligible companies.
Sheila Shaigany, MD, FAAD
Blueprint Medicines – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria), Investigator(No Compensation Received); Hoth Therapeutics – Investigator(No Compensation Received); Priovant Therapeutics – Consultant (1099 relationship)(Honoraria), Investigator(No Compensation Received);
Emily Sheetz, MS
No financial relationships exist with ineligible companies.
Kevin Tabatabaei
No financial relationships exist with ineligible companies.